Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$8.65 ▼ -0.02
(-0.23%)
MKT CAP: $661.9M • VOL: 741.0K
52W L $4 52W H $14
ROARABLE / RQD
D- • 38/100
PIOTROSKI
2 / 9
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$7
MEDIAN
$10
MEAN
$10
HIGH
$12
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE CADL TAPE
CADL // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $10.47 | $9.95 | 2025-02-14 | $7.87 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $10.90 | $10.21 | 2025-02-06 | $8.13 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $9.86 | $9.52 | 2025-01-29 | $8.30 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $8.82 | — | 2025-01-17 | $8.48 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $7.61 | $8.22 | 2025-01-09 | $7.70 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $10.29 | $9.00 | 2024-12-18 | $7.53 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $8.39 | $8.74 | 2024-12-04 | $8.04 | -4.3% | 48% | C |